var data={"title":"Pralatrexate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pralatrexate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/395285?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pralatrexate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pralatrexate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9407902\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Folotyn</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410906\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Antimetabolite;</li>\n      <li>\n        Antineoplastic Agent, Antimetabolite (Antifolate)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410995\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Initiate vitamin supplements before initial pralatrexate dose: Folic acid 1 to 1.25 mg/day orally beginning 10 days prior to initial pralatrexate dose; continue during treatment and for 30 days after last pralatrexate dose; vitamin B<sub>12</sub> 1,000 mcg IM within 10 weeks prior to initial pralatrexate dose and every 8 to 10 weeks thereafter (after first dose, subsequent B<sub>12</sub> doses may be administered on the same day as pralatrexate).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prior to administering any dose, mucositis should be &le;grade 1 and absolute neutrophil count (ANC) should be &ge;1,000/mm<sup>3</sup>; platelets should be &ge;100,000/mm<sup>3</sup> for the first dose and &ge;50,000/mm<sup>3</sup> for subsequent doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Peripheral T-cell lymphoma (PTCL), relapsed or refractory:</b> IV: 30 mg/m<sup>2</sup> once weekly for 6 weeks of a 7-week treatment cycle; continue until disease progression or unacceptable toxicity (O&rsquo;Connor 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cutaneous T-cell lymphoma, relapsed or refractory (off-label use):</b> IV: 15 mg/m<sup>2</sup> once weekly for 3 weeks of a 4-week treatment cycle (Horwitz 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410951\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410954\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Peripheral T-cell lymphoma (PTCL), relapsed or refractory: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Estimated glomerular filtration rate (eGFR) &ge;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">eGFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>: Initial: Reduce dose to 15 mg/m<sup>2</sup>; if dose reductions for toxicity are necessary, reduce each dose to 10 mg/m<sup>2</sup>. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">End-stage renal disease (ESRD), including dialysis: Avoid use (unless the potential benefit outweighs risks). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410955\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Patients with total bilirubin &gt;1.5 mg/dL, AST or ALT &gt;2.5 times the upper limit of normal (ULN), or ALT or AST &gt;5 times ULN if documented hepatic lymphoma involvement were excluded from clinical trials. Persistent abnormalities may indicate hepatotoxicity requiring dosage modification:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Grade 3 (AST or ALT &gt;5 to 20 times ULN or bilirubin &gt;3 to 10 times ULN): Omit dose; decrease to 20 mg/m<sup>2</sup> when recovers to &le;grade 2</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Grade 4 (AST or ALT &gt;20 times ULN or bilirubin &gt;10 times ULN): Discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20343887\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer: </i> Utilize patient&rsquo;s actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410952\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">Severe or intolerable adverse events may require dose omission, reduction or interruption. Do not make up omitted doses at the end of a cycle; do not re-escalate dose after a reduction due to toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Hematologic toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <i>Platelets:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">&lt;50,000/mm<sup>3</sup> (for 1-week duration): Omit dose; continue at previous dose if platelets recover within 1 week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">&lt;50,000/mm<sup>3</sup> (for 2-week duration): Omit dose; decrease to 20 mg/m<sup>2</sup> (10 mg/m<sup>2</sup> in patients with eGFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>) if platelets recover within 2 weeks  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">&lt;50,000/mm<sup>3</sup> (for 3-week duration): Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <i>ANC:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">500 to 1,000/mm<sup>3</sup> without fever (for 1-week duration): Omit dose; continue at previous dose if ANC recovers within 1 week  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">500 to 1,000/mm<sup>3</sup> with fever <b>or</b> ANC &lt;500/mm<sup>3</sup> (for 1-week duration): Omit dose, give filgrastim or sargramostim support; continue at previous dose (with growth factor support) if ANC recovers within 1 week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">500 to 1,000/mm<sup>3</sup> with fever <b>or</b> ANC &lt;500/mm<sup>3</sup> (recurrent or for 2-week duration): Omit dose and give filgrastim or sargramostim support; decrease to 20 mg/m<sup>2</sup> (10 mg/m<sup>2</sup> in patients with eGFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>) with growth factor support  if ANC recovers within 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">500 to 1,000/mm<sup>3</sup> with fever <b>or</b> ANC &lt;500/mm<sup>3</sup> (second recurrence or for 3 week duration): Discontinue treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Nonhematologic toxicity: Mucositis (on day of treatment):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 2: Omit dose; continue at previous dose when recovers to &le; grade 1</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 or recurrent grade 2: Omit dose and decrease to 20 mg/m<sup>2</sup> (10 mg/m<sup>2</sup> in patients with eGFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>) when recovers to &le;grade 1</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Nonhematologic toxicity (other than mucositis):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Grade 3: Omit dose; decrease to 20 mg/m<sup>2</sup> (10 mg/m<sup>2</sup> in patients with eGFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>) when recovers to &le; grade 2</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Grade 4: Discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9411001\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Folotyn: 20 mg/mL (1 mL); 40 mg/2 mL (2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410904\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410996\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer IV push (undiluted) over 3 to 5 minutes into the line of a free-flowing normal saline IV</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132749\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410907\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Peripheral T-cell lymphoma:</b> Treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25471049\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cutaneous T-cell lymphomas (relapsed or refractory)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9407900\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PRALAtrexate may be confused with methotrexate, PEMEtrexed, raltitrexed </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Folotyn may be confused with Focalin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410916\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (30%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (36%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (15%), pruritus (14%; grade 3: 2%), night sweats (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Mucositis (70%; grade 3: 17%; grade 4: 4%), nausea (40%), constipation (33%), vomiting (25%), diarrhea (21%), anorexia (15%), abdominal pain (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (41%; grade 3: 14%; grade 4: 19%), anemia (34%; grade 3: 15%; grade 4: 2%), neutropenia (24%; grade 3: 13%; grade 4: 7%), leukopenia (11%; grade 3: 3%; grade 4: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (13%; grade 3: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Limb pain (12%), back pain (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (28%), epistaxis (26%), dyspnea (19%), pharyngolaryngeal pain (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (32%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Tachycardia (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Severe dehydration (&gt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Febrile neutropenia (serious: &gt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis (serious: &gt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Dermal ulcer, desquamation, intestinal obstruction, lymphocytopenia, odynophagia, pancytopenia, toxic epidermal necrolysis, tumor lysis syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410913\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410914\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: May cause thrombocytopenia, neutropenia and anemia; may require dosage modification. Monitor blood counts. Prophylactic folic acid and vitamin B<sub>12</sub> supplements are necessary to reduce hematologic toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Severe and potentially fatal dermatologic reactions, including skin exfoliation, ulceration, and toxic epidermal necrolysis (TEN), have been reported. Skin reaction may be progressive; severity may increase with continued treatment; may also involve skin and subcutaneous tissues which are affected by lymphoma. Monitor all dermatologic reactions closely; withhold or discontinue treatment for severe dermatologic reaction.   </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Hepatotoxicity and liver function test abnormalities have been observed with use. Monitor liver function. Persistent abnormalities may indicate hepatotoxicity and may require dosage modification or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mucositis: Pralatrexate may cause mucositis (includes stomatitis or mucosal inflammation of gastrointestinal and genitourinary tracts). Monitor weekly; may require dosage modification. Prophylactic folic acid and vitamin B<sub>12</sub> supplements are necessary to reduce treatment-related mucositis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome (TLS): Pralatrexate may cause (TLS). Monitor closely; if TLS develops, treat for associated complications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Patients with moderate to severe renal impairment are at higher risk for increased exposure and toxicity. Monitor renal function and for systemic toxicity due to increased exposure. Dosage adjustment is recommended in patients with severe renal impairment (eGFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>). Unless the potential benefits outweigh potential risks, avoid use in patients with end-stage renal disease (ESRD), including patients undergoing dialysis. Serious adverse reactions, including toxic epidermal necrolysis and mucositis were reported in patients with ESRD undergoing dialysis. Concurrent use with drugs with substantial renal clearance (eg, NSAIDs, sulfamethoxazole/trimethoprim) may result in delayed pralatrexate clearance. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299929\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9419305\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9530&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate. Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of PRALAtrexate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyrimethamine: May enhance the adverse/toxic effect of PRALAtrexate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sapropterin: PRALAtrexate may decrease the serum concentration of Sapropterin. Specifically, pralatrexate may decrease tissue concentrations of tetrahydrobiopterin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfamethoxazole: May increase the serum concentration of PRALAtrexate. More specifically, sulfamethoxazole may decrease excretion of pralatrexate. Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of sulfamethoxazole. Monitor for decreased pralatrexate levels with discontinuation of sulfamethoxazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May increase the serum concentration of PRALAtrexate. More specifically, trimethoprim may decrease excretion of pralatrexate. Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of trimethoprim. Monitor for decreased pralatrexate levels with discontinuation of trimethoprim.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410908\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410909\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were observed in animal reproduction studies. May cause fetal harm if administered to a pregnant woman.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410912\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if pralatrexate is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made to discontinue breast-feeding or to discontinue pralatrexate, taking into account the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410999\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential (baseline and weekly), serum chemistries, including renal and liver function tests (prior to the first and fourth doses in each cycle); mucositis severity (baseline and weekly); monitor for signs of tumor lysis syndrome and for dermatologic reactions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410993\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Antifolate analog; inhibits DNA, RNA, and protein synthesis by selectively entering cells expressing reduced folate carrier (RFC-1), is polyglutamylated by folylpolyglutamate synthetase (FPGS) and then competes for the DHFR-folate binding site to inhibit dihydrofolate reductase (DHFR)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9410945\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: <i>S</i>-diastereomer: 105 L; <i>R</i>-diastereomer: 37 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~67%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not significantly metabolized by phase I hepatic isoenzymes or phase II glucuronidases.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 12 to 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~34% as unchanged drug; parent drug [racemic pralatrexate]: ~39%); Feces (34%); Respiratory (10% [exhaled])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322721\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Folotyn Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (1 mL): $6,057.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/2 mL (2 mL): $12,115.13</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27001183\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Difolta (IL, JP);</li>\n      <li>Folotyn (BB, CH, KR, SG)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Folotyn (pralatrexate) [prescribing information]. Westminster, CO: Allos Therapeutics Inc; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al. Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline.<i> J Clin Oncol</i>. 2012;30(13):1553-1561.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralatrexate-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22394596\"></a>Horwitz SM, Kim YH, Foss F, et al. Identification of an Active, Well-Tolerated Dose of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma. <i>Blood</i>. 2012;119(18):4115-4122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralatrexate-drug-information/abstract-text/22394596/pubmed\" target=\"_blank\" id=\"22394596\">22394596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Izbicka E, Diaz A, Streeper R, et al. Distinct Mechanistic Activity Profile of Pralatrexate in Comparison to Other Antifolates in <i>in vitro</i> and <i>in vivo</i> Models of Human Cancers. <i>Cancer Chemother Pharmacol</i>. 2009;64(5): 993-999.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralatrexate-drug-information/abstract-text/19221750/pubmed\" target=\"_blank\" id=\"19221750\">19221750</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Multinational Association of Supportive Care in Cancer. MASCC/ESMO antiemetic guideline 2016. http://www.mascc.org/assets/Guidelines-Tools/mascc_antiemetic_guidelines_english_2016_v.1.2.pdf. Accessed June 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O&rsquo;Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies. <i>J Clin Oncol</i>. 2009; 27(26):4357-4364.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralatrexate-drug-information/abstract-text/19652067/pubmed\" target=\"_blank\" id=\"19652067\">19652067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results from the Pivotal PROPEL Study. <i>J Clin Oncol</i>. 2011;29(9):1182-1189.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralatrexate-drug-information/abstract-text/21245435/pubmed\" target=\"_blank\" id=\"21245435\">21245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9530 Version 120.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9407902\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9410906\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9410995\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9410951\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F9410954\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F9410955\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20343887\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F9410952\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9411001\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9410904\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9410996\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132749\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9410907\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25471049\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9407900\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9410916\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9410913\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9410914\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299929\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9419305\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9410908\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9410909\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9410912\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9410999\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9410993\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9410945\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322721\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F27001183\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9530|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pralatrexate-patient-drug-information\" class=\"drug drug_patient\">Pralatrexate: Patient drug information</a></li></ul></div></div>","javascript":null}